Snapshots from the Edge | Artem Sorokin Explains How Today’s AI Capabilities Open the Door to Real Impacts in Drug Discovery

“Today, with unsupervised learning, we can build AI models without spending a lot of time and effort labelling all of the information. We look for the proprietary data that contains intelligence, or associations between different meanings. We can build a foundational model on top, for example using LLMs with retrieval and augmented generations, to enable this intelligence to work for the benefit of the organization.”

Friend and partner Artem Sorokin, CEO of CrackenAGI, explains how today’s AI capabilities open the door to real impacts in drug discovery.